Sign in
CompletedPhase 4

NICU Antibiotics and Outcomes Trial

Key facts

Who runs it
Michael Morowitz
Where
Hershey, Louisville, Mobile, New Haven, New York, Philadelphia, Pittsburgh, Rochester, San Antonio, San Diego, Tampa, Valhalla, and Winston-Salem, United StatesSee the 14 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
359 people enrolled
Started
5 Aug 2020
Ended
15 Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ampicillin
  • Gentamycin
  • Normal saline
Record updated
24 April 2026

Who can take part

Age
Up to 4 hours
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Other criteria

  • Inclusion criteria: We will enroll newborn infants with gestational age of 23-30 weeks 6 days infants at participating study sites will be eligible
  • Exclusion criteria:
  • Infants born for maternal indications via caesarean section with rupture of membranes at delivery, without attempts to induce labor, and without concern for maternal infection
  • Infants at high risk of EOS; Infants born to mothers with intrapartum fever (> 38C) or clinical diagnosis of chorioamnionitis; Infants born to mothers with previous infant with GBS disease/infection
  • Infants with respiratory insufficiency requiring invasive mechanical ventilation and FiO2 > 0.40 or non-invasive ventilation and FiO2 > 0.60 at time of randomization
  • Infants with ongoing hemodynamic instability requiring vasopressors or fluid boluses at time of randomization
  • Clinician concern infant is at high risk for sepsis due to infant physical exam findings or clinical history of mother or infant
  • Major congenital anomalies
  • Infants not anticipated to survive beyond 72 hours
  • Infants who have received antibiotics prior to randomization
  • Mothers that are <18 years old at time of enrollment

Where in United States

  • Penn State Medical CollegeHershey, United States
  • University of Louisville Research Foundation Inc./Kosair Charities Pediatric Clinical Research UnitLouisville, United States
  • USA Children's and Women's HospitalMobile, United States
  • Yale University School Of MedicineNew Haven, United States
  • The Trustees of Columbia University in the City of New YorkNew York, United States
  • Alfred I. duPont for Children of the Nemours FoundationPhiladelphia, United States
  • Pennsylvania Hospital/The Children's Hospital of PhiladelphiaPhiladelphia, United States
  • Magee-Womens HospitalPittsburgh, United States
  • Golisano Children's Hospital at University of RochesterRochester, United States
  • University of Texas Health Science Center at San AntonioSan Antonio, United States
  • Sharp Mary Birch Hospital for Women & NewbornsSan Diego, United States
  • University of South Flordia HealthTampa, United States
  • Maria Fareri Children's Hospital at Westchester Medical CenterValhalla, United States
  • Atrium Health Wake Forest BaptistWinston-Salem, United States

About the trial

What the trial wants to find out

The goal of the NANO trial is to study the longstanding clinical practice of empirically administering intravenous antibiotics to extremely low birthweight (ELBW) infants in the first days of life. In this 802-subject multicenter placebo-controlled randomized clinical trial, the hypothesis to be tested is that the incidence of adverse outcomes is higher in babies receiving empiric antibiotics (EA) in the first week of life compared to babies receiving placebo. The study targets a population of ELBW infants in whom the clinical decision to use or not use EA is currently most challenging -- infants that are clinically stable that did not have a known exposure to intraamniotic infection and were not born preterm for maternal indications. The primary outcome is the composite outcome of late-onset sepsis (LOS), necrotizing enterocolitis (NEC), or death during the index hospitalization. Secondary safety outcomes will include total antibiotic days, days to full enteral feedings, and common morbidities in preterm infants that have previously been linked to EA, e.g. retinopathy of prematurity and bronchopulmonary dysplasia. Weight and length z-score, and head circumference, are standard measures to be collected weekly by clinical team per a standardized protocol.

The 2 groups in the trial

  • Empiric antibioticsExisting treatment, for comparison

    Infants will receive standard antibiotic coverage of ampicillin and gentamycin at site approved dosing guidelines while completing an evaluation for early-onset neonatal sepsis.

    Treatment: Ampicillin and Gentamycin

  • PlaceboPlacebo, for comparison

    Infants will receive a volume matched placebo of normal saline while completing an evaluation for early-onset neonatal sepsis.

    Treatment: Normal saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
24 April 2026